ARTICLE | Clinical News
SAR3419: Phase II started
October 31, 2011 7:00 AM UTC
Sanofi began a Phase II trial evaluating SAR3419. The trial start triggers a $3 million milestone payment to ImmunoGen from Sanofi under a 2003 deal to develop cancer antibodies (see BioCentury, Aug. ...